The presence of the IDH mutation is associated with a significantly better prognosis compared to IDH–wild-type gliomas, and its identification is, therefore, very important for the classification of cerebral gliomas and for clinical therapeutic management. This evidence concerns the gene IDH2 and central nervous system cancer.